nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—Myocarditis—Doxorubicin—sarcoma	0.0168	0.0182	CcSEcCtD
Methyldopa—Bone marrow depression—Vincristine—sarcoma	0.0144	0.0157	CcSEcCtD
Methyldopa—Bone marrow depression—Mitoxantrone—sarcoma	0.0141	0.0153	CcSEcCtD
Methyldopa—Endocrine disorder—Thiotepa—sarcoma	0.0133	0.0144	CcSEcCtD
Methyldopa—Amenorrhoea—Thiotepa—sarcoma	0.0125	0.0136	CcSEcCtD
Methyldopa—Amenorrhoea—Mitoxantrone—sarcoma	0.0108	0.0117	CcSEcCtD
Methyldopa—Colitis—Thiotepa—sarcoma	0.0106	0.0115	CcSEcCtD
Methyldopa—Pericarditis—Epirubicin—sarcoma	0.0102	0.0111	CcSEcCtD
Methyldopa—Pericarditis—Doxorubicin—sarcoma	0.00948	0.0103	CcSEcCtD
Methyldopa—Cardiac failure congestive—Mitoxantrone—sarcoma	0.0076	0.00825	CcSEcCtD
Methyldopa—DDC—embryo—sarcoma	0.0076	0.097	CbGeAlD
Methyldopa—Liver function test abnormal—Dactinomycin—sarcoma	0.00732	0.00794	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Dactinomycin—sarcoma	0.00714	0.00774	CcSEcCtD
Methyldopa—Bone marrow depression—Epirubicin—sarcoma	0.00656	0.00712	CcSEcCtD
Methyldopa—Pancytopenia—Thiotepa—sarcoma	0.00655	0.00711	CcSEcCtD
Methyldopa—Pancytopenia—Dactinomycin—sarcoma	0.0065	0.00706	CcSEcCtD
Methyldopa—Cardiac failure congestive—Etoposide—sarcoma	0.00632	0.00686	CcSEcCtD
Methyldopa—Weight increased—Thiotepa—sarcoma	0.00628	0.00681	CcSEcCtD
Methyldopa—Infestation NOS—Thiotepa—sarcoma	0.00615	0.00668	CcSEcCtD
Methyldopa—Infestation—Thiotepa—sarcoma	0.00615	0.00668	CcSEcCtD
Methyldopa—Bone marrow depression—Doxorubicin—sarcoma	0.00607	0.00659	CcSEcCtD
Methyldopa—Jaundice—Thiotepa—sarcoma	0.006	0.00651	CcSEcCtD
Methyldopa—Hepatobiliary disease—Thiotepa—sarcoma	0.00582	0.00631	CcSEcCtD
Methyldopa—Pancytopenia—Vincristine—sarcoma	0.00581	0.00631	CcSEcCtD
Methyldopa—Agranulocytosis—Thiotepa—sarcoma	0.00574	0.00623	CcSEcCtD
Methyldopa—Agranulocytosis—Dactinomycin—sarcoma	0.0057	0.00618	CcSEcCtD
Methyldopa—Pancytopenia—Mitoxantrone—sarcoma	0.00566	0.00614	CcSEcCtD
Methyldopa—Erectile dysfunction—Vincristine—sarcoma	0.00564	0.00611	CcSEcCtD
Methyldopa—Erectile dysfunction—Mitoxantrone—sarcoma	0.00549	0.00596	CcSEcCtD
Methyldopa—Hepatitis—Dactinomycin—sarcoma	0.00548	0.00595	CcSEcCtD
Methyldopa—Connective tissue disorder—Thiotepa—sarcoma	0.00543	0.00589	CcSEcCtD
Methyldopa—Weight increased—Mitoxantrone—sarcoma	0.00542	0.00588	CcSEcCtD
Methyldopa—Liver injury—Epirubicin—sarcoma	0.00526	0.00571	CcSEcCtD
Methyldopa—COMT—myometrium—sarcoma	0.00522	0.0667	CbGeAlD
Methyldopa—Jaundice—Mitoxantrone—sarcoma	0.00518	0.00562	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Etoposide—sarcoma	0.00516	0.0056	CcSEcCtD
Methyldopa—Cardiac disorder—Thiotepa—sarcoma	0.00513	0.00556	CcSEcCtD
Methyldopa—Amenorrhoea—Epirubicin—sarcoma	0.00504	0.00547	CcSEcCtD
Methyldopa—Angiopathy—Thiotepa—sarcoma	0.00501	0.00544	CcSEcCtD
Methyldopa—Mediastinal disorder—Thiotepa—sarcoma	0.00498	0.0054	CcSEcCtD
Methyldopa—Agranulocytosis—Mitoxantrone—sarcoma	0.00496	0.00538	CcSEcCtD
Methyldopa—Liver injury—Doxorubicin—sarcoma	0.00487	0.00528	CcSEcCtD
Methyldopa—Bradycardia—Mitoxantrone—sarcoma	0.00486	0.00527	CcSEcCtD
Methyldopa—Mental disorder—Thiotepa—sarcoma	0.00484	0.00525	CcSEcCtD
Methyldopa—Connective tissue disorder—Vincristine—sarcoma	0.00481	0.00522	CcSEcCtD
Methyldopa—Hepatitis—Mitoxantrone—sarcoma	0.00477	0.00518	CcSEcCtD
Methyldopa—COMT—seminal vesicle—sarcoma	0.00472	0.0603	CbGeAlD
Methyldopa—Pancytopenia—Etoposide—sarcoma	0.00471	0.00511	CcSEcCtD
Methyldopa—Amenorrhoea—Doxorubicin—sarcoma	0.00466	0.00506	CcSEcCtD
Methyldopa—Cardiac disorder—Vincristine—sarcoma	0.00455	0.00493	CcSEcCtD
Methyldopa—COMT—hematopoietic system—sarcoma	0.00449	0.0573	CbGeAlD
Methyldopa—Angiopathy—Vincristine—sarcoma	0.00444	0.00482	CcSEcCtD
Methyldopa—Hepatocellular injury—Epirubicin—sarcoma	0.00443	0.00481	CcSEcCtD
Methyldopa—Infestation NOS—Etoposide—sarcoma	0.00442	0.0048	CcSEcCtD
Methyldopa—Infestation—Etoposide—sarcoma	0.00442	0.0048	CcSEcCtD
Methyldopa—Mediastinal disorder—Vincristine—sarcoma	0.00441	0.00479	CcSEcCtD
Methyldopa—Jaundice—Etoposide—sarcoma	0.00431	0.00467	CcSEcCtD
Methyldopa—Leukopenia—Thiotepa—sarcoma	0.0043	0.00467	CcSEcCtD
Methyldopa—Mental disorder—Vincristine—sarcoma	0.00429	0.00466	CcSEcCtD
Methyldopa—Leukopenia—Dactinomycin—sarcoma	0.00427	0.00463	CcSEcCtD
Methyldopa—Colitis—Epirubicin—sarcoma	0.00425	0.00461	CcSEcCtD
Methyldopa—Hepatobiliary disease—Etoposide—sarcoma	0.00418	0.00454	CcSEcCtD
Methyldopa—Agranulocytosis—Etoposide—sarcoma	0.00412	0.00448	CcSEcCtD
Methyldopa—Hepatocellular injury—Doxorubicin—sarcoma	0.0041	0.00445	CcSEcCtD
Methyldopa—Myalgia—Thiotepa—sarcoma	0.00409	0.00444	CcSEcCtD
Methyldopa—Arthralgia—Thiotepa—sarcoma	0.00409	0.00444	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00407	0.00441	CcSEcCtD
Methyldopa—Myalgia—Dactinomycin—sarcoma	0.00406	0.00441	CcSEcCtD
Methyldopa—COMT—smooth muscle tissue—sarcoma	0.00395	0.0504	CbGeAlD
Methyldopa—Colitis—Doxorubicin—sarcoma	0.00393	0.00427	CcSEcCtD
Methyldopa—COMT—skin of body—sarcoma	0.0039	0.0498	CbGeAlD
Methyldopa—Infection—Thiotepa—sarcoma	0.0039	0.00423	CcSEcCtD
Methyldopa—Oedema—Dactinomycin—sarcoma	0.00389	0.00423	CcSEcCtD
Methyldopa—Infection—Dactinomycin—sarcoma	0.00387	0.0042	CcSEcCtD
Methyldopa—Nervous system disorder—Thiotepa—sarcoma	0.00385	0.00418	CcSEcCtD
Methyldopa—Thrombocytopenia—Thiotepa—sarcoma	0.00384	0.00417	CcSEcCtD
Methyldopa—Leukopenia—Vincristine—sarcoma	0.00382	0.00414	CcSEcCtD
Methyldopa—Thrombocytopenia—Dactinomycin—sarcoma	0.00381	0.00414	CcSEcCtD
Methyldopa—Skin disorder—Thiotepa—sarcoma	0.00381	0.00414	CcSEcCtD
Methyldopa—DDC—testis—sarcoma	0.00372	0.0475	CbGeAlD
Methyldopa—Leukopenia—Mitoxantrone—sarcoma	0.00372	0.00403	CcSEcCtD
Methyldopa—Cardiac disorder—Etoposide—sarcoma	0.00368	0.004	CcSEcCtD
Methyldopa—Myalgia—Vincristine—sarcoma	0.00363	0.00394	CcSEcCtD
Methyldopa—Angiopathy—Etoposide—sarcoma	0.0036	0.00391	CcSEcCtD
Methyldopa—Eczema—Epirubicin—sarcoma	0.00358	0.00388	CcSEcCtD
Methyldopa—Mediastinal disorder—Etoposide—sarcoma	0.00358	0.00388	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00358	0.00388	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00355	0.00385	CcSEcCtD
Methyldopa—Cardiac failure congestive—Epirubicin—sarcoma	0.00355	0.00385	CcSEcCtD
Methyldopa—Arthralgia—Mitoxantrone—sarcoma	0.00354	0.00384	CcSEcCtD
Methyldopa—Myalgia—Mitoxantrone—sarcoma	0.00354	0.00384	CcSEcCtD
Methyldopa—Paraesthesia—Thiotepa—sarcoma	0.00352	0.00382	CcSEcCtD
Methyldopa—DDC—liver—sarcoma	0.00351	0.0449	CbGeAlD
Methyldopa—Oedema—Vincristine—sarcoma	0.00348	0.00378	CcSEcCtD
Methyldopa—Infection—Vincristine—sarcoma	0.00346	0.00375	CcSEcCtD
Methyldopa—Nervous system disorder—Vincristine—sarcoma	0.00341	0.0037	CcSEcCtD
Methyldopa—Thrombocytopenia—Vincristine—sarcoma	0.00341	0.0037	CcSEcCtD
Methyldopa—COMT—cardiac atrium—sarcoma	0.00341	0.0435	CbGeAlD
Methyldopa—Oedema—Mitoxantrone—sarcoma	0.00339	0.00368	CcSEcCtD
Methyldopa—COMT—uterus—sarcoma	0.00339	0.0433	CbGeAlD
Methyldopa—Gastrointestinal disorder—Thiotepa—sarcoma	0.00339	0.00368	CcSEcCtD
Methyldopa—Infection—Mitoxantrone—sarcoma	0.00337	0.00365	CcSEcCtD
Methyldopa—Constipation—Thiotepa—sarcoma	0.00336	0.00364	CcSEcCtD
Methyldopa—Thrombocytopenia—Mitoxantrone—sarcoma	0.00332	0.0036	CcSEcCtD
Methyldopa—Eczema—Doxorubicin—sarcoma	0.00331	0.00359	CcSEcCtD
Methyldopa—Skin disorder—Mitoxantrone—sarcoma	0.00329	0.00357	CcSEcCtD
Methyldopa—Cardiac failure congestive—Doxorubicin—sarcoma	0.00328	0.00356	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Vincristine—sarcoma	0.00317	0.00344	CcSEcCtD
Methyldopa—Paraesthesia—Vincristine—sarcoma	0.00312	0.00339	CcSEcCtD
Methyldopa—Body temperature increased—Thiotepa—sarcoma	0.0031	0.00337	CcSEcCtD
Methyldopa—Leukopenia—Etoposide—sarcoma	0.00309	0.00335	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00309	0.00335	CcSEcCtD
Methyldopa—Body temperature increased—Dactinomycin—sarcoma	0.00308	0.00334	CcSEcCtD
Methyldopa—Paraesthesia—Mitoxantrone—sarcoma	0.00304	0.0033	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Vincristine—sarcoma	0.003	0.00326	CcSEcCtD
Methyldopa—Constipation—Vincristine—sarcoma	0.00298	0.00323	CcSEcCtD
Methyldopa—COMT—tendon—sarcoma	0.00297	0.0379	CbGeAlD
Methyldopa—Liver function test abnormal—Epirubicin—sarcoma	0.00297	0.00322	CcSEcCtD
Methyldopa—Orthostatic hypotension—Epirubicin—sarcoma	0.00294	0.00319	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00292	0.00317	CcSEcCtD
Methyldopa—Breast disorder—Epirubicin—sarcoma	0.00291	0.00315	CcSEcCtD
Methyldopa—Constipation—Mitoxantrone—sarcoma	0.0029	0.00314	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.0029	0.00314	CcSEcCtD
Methyldopa—Hypersensitivity—Thiotepa—sarcoma	0.00289	0.00314	CcSEcCtD
Methyldopa—COMT—bone marrow—sarcoma	0.00288	0.0367	CbGeAlD
Methyldopa—Hypersensitivity—Dactinomycin—sarcoma	0.00287	0.00311	CcSEcCtD
Methyldopa—Asthenia—Thiotepa—sarcoma	0.00282	0.00305	CcSEcCtD
Methyldopa—Infection—Etoposide—sarcoma	0.0028	0.00304	CcSEcCtD
Methyldopa—Abdominal distension—Epirubicin—sarcoma	0.0028	0.00304	CcSEcCtD
Methyldopa—Asthenia—Dactinomycin—sarcoma	0.00279	0.00303	CcSEcCtD
Methyldopa—Thrombocytopenia—Etoposide—sarcoma	0.00276	0.00299	CcSEcCtD
Methyldopa—Eosinophilia—Epirubicin—sarcoma	0.00275	0.00298	CcSEcCtD
Methyldopa—Body temperature increased—Vincristine—sarcoma	0.00275	0.00298	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—sarcoma	0.00275	0.00298	CcSEcCtD
Methyldopa—Skin disorder—Etoposide—sarcoma	0.00274	0.00297	CcSEcCtD
Methyldopa—Pancreatitis—Epirubicin—sarcoma	0.00272	0.00296	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—sarcoma	0.00272	0.00295	CcSEcCtD
Methyldopa—Angina pectoris—Epirubicin—sarcoma	0.00271	0.00294	CcSEcCtD
Methyldopa—DDC—lymph node—sarcoma	0.00269	0.0344	CbGeAlD
Methyldopa—Breast disorder—Doxorubicin—sarcoma	0.00269	0.00292	CcSEcCtD
Methyldopa—Diarrhoea—Thiotepa—sarcoma	0.00269	0.00291	CcSEcCtD
Methyldopa—Body temperature increased—Mitoxantrone—sarcoma	0.00268	0.00291	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.00268	0.00291	CcSEcCtD
Methyldopa—Diarrhoea—Dactinomycin—sarcoma	0.00266	0.00289	CcSEcCtD
Methyldopa—ADRA2A—myometrium—sarcoma	0.00266	0.034	CbGeAlD
Methyldopa—Pancytopenia—Epirubicin—sarcoma	0.00264	0.00286	CcSEcCtD
Methyldopa—SLC15A1—liver—sarcoma	0.00261	0.0334	CbGeAlD
Methyldopa—Dizziness—Thiotepa—sarcoma	0.0026	0.00282	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—sarcoma	0.00259	0.00281	CcSEcCtD
Methyldopa—Hypersensitivity—Vincristine—sarcoma	0.00256	0.00278	CcSEcCtD
Methyldopa—Eosinophilia—Doxorubicin—sarcoma	0.00255	0.00276	CcSEcCtD
Methyldopa—Paraesthesia—Etoposide—sarcoma	0.00253	0.00275	CcSEcCtD
Methyldopa—Weight increased—Epirubicin—sarcoma	0.00253	0.00274	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—sarcoma	0.00252	0.00273	CcSEcCtD
Methyldopa—Angina pectoris—Doxorubicin—sarcoma	0.0025	0.00272	CcSEcCtD
Methyldopa—Hypersensitivity—Mitoxantrone—sarcoma	0.0025	0.00271	CcSEcCtD
Methyldopa—Asthenia—Vincristine—sarcoma	0.0025	0.00271	CcSEcCtD
Methyldopa—Vomiting—Thiotepa—sarcoma	0.0025	0.00271	CcSEcCtD
Methyldopa—Infestation NOS—Epirubicin—sarcoma	0.00248	0.00269	CcSEcCtD
Methyldopa—Infestation—Epirubicin—sarcoma	0.00248	0.00269	CcSEcCtD
Methyldopa—Vomiting—Dactinomycin—sarcoma	0.00248	0.00269	CcSEcCtD
Methyldopa—Rash—Thiotepa—sarcoma	0.00247	0.00268	CcSEcCtD
Methyldopa—Dermatitis—Thiotepa—sarcoma	0.00247	0.00268	CcSEcCtD
Methyldopa—Headache—Thiotepa—sarcoma	0.00246	0.00267	CcSEcCtD
Methyldopa—COMT—testis—sarcoma	0.00246	0.0314	CbGeAlD
Methyldopa—Rash—Dactinomycin—sarcoma	0.00246	0.00266	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—sarcoma	0.00244	0.00265	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Etoposide—sarcoma	0.00243	0.00264	CcSEcCtD
Methyldopa—Asthenia—Mitoxantrone—sarcoma	0.00243	0.00264	CcSEcCtD
Methyldopa—Jaundice—Epirubicin—sarcoma	0.00241	0.00262	CcSEcCtD
Methyldopa—Constipation—Etoposide—sarcoma	0.00241	0.00262	CcSEcCtD
Methyldopa—ADRA2A—seminal vesicle—sarcoma	0.0024	0.0307	CbGeAlD
Methyldopa—Diarrhoea—Vincristine—sarcoma	0.00238	0.00258	CcSEcCtD
Methyldopa—Hepatobiliary disease—Epirubicin—sarcoma	0.00234	0.00254	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—sarcoma	0.00234	0.00254	CcSEcCtD
Methyldopa—Nausea—Thiotepa—sarcoma	0.00233	0.00253	CcSEcCtD
Methyldopa—COMT—liver—sarcoma	0.00232	0.0297	CbGeAlD
Methyldopa—Diarrhoea—Mitoxantrone—sarcoma	0.00232	0.00252	CcSEcCtD
Methyldopa—Nausea—Dactinomycin—sarcoma	0.00231	0.00251	CcSEcCtD
Methyldopa—Agranulocytosis—Epirubicin—sarcoma	0.00231	0.00251	CcSEcCtD
Methyldopa—Dizziness—Vincristine—sarcoma	0.0023	0.0025	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—sarcoma	0.00229	0.00249	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—sarcoma	0.00229	0.00249	CcSEcCtD
Methyldopa—ADRA2A—hematopoietic system—sarcoma	0.00228	0.0292	CbGeAlD
Methyldopa—Bradycardia—Epirubicin—sarcoma	0.00226	0.00246	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—sarcoma	0.00223	0.00242	CcSEcCtD
Methyldopa—Body temperature increased—Etoposide—sarcoma	0.00223	0.00242	CcSEcCtD
Methyldopa—Hepatitis—Epirubicin—sarcoma	0.00222	0.00241	CcSEcCtD
Methyldopa—Vomiting—Vincristine—sarcoma	0.00221	0.0024	CcSEcCtD
Methyldopa—ADRA2A—connective tissue—sarcoma	0.0022	0.0281	CbGeAlD
Methyldopa—Rash—Vincristine—sarcoma	0.00219	0.00238	CcSEcCtD
Methyldopa—Dermatitis—Vincristine—sarcoma	0.00219	0.00238	CcSEcCtD
Methyldopa—Connective tissue disorder—Epirubicin—sarcoma	0.00219	0.00237	CcSEcCtD
Methyldopa—Headache—Vincristine—sarcoma	0.00218	0.00237	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—sarcoma	0.00217	0.00235	CcSEcCtD
Methyldopa—Vomiting—Mitoxantrone—sarcoma	0.00215	0.00234	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—sarcoma	0.00214	0.00232	CcSEcCtD
Methyldopa—Rash—Mitoxantrone—sarcoma	0.00214	0.00232	CcSEcCtD
Methyldopa—Dermatitis—Mitoxantrone—sarcoma	0.00213	0.00232	CcSEcCtD
Methyldopa—Headache—Mitoxantrone—sarcoma	0.00212	0.0023	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—sarcoma	0.0021	0.00227	CcSEcCtD
Methyldopa—Hypersensitivity—Etoposide—sarcoma	0.00208	0.00225	CcSEcCtD
Methyldopa—Nausea—Vincristine—sarcoma	0.00207	0.00224	CcSEcCtD
Methyldopa—Cardiac disorder—Epirubicin—sarcoma	0.00206	0.00224	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—sarcoma	0.00206	0.00223	CcSEcCtD
Methyldopa—Asthenia—Etoposide—sarcoma	0.00202	0.00219	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—sarcoma	0.00202	0.00219	CcSEcCtD
Methyldopa—Angiopathy—Epirubicin—sarcoma	0.00202	0.00219	CcSEcCtD
Methyldopa—Nausea—Mitoxantrone—sarcoma	0.00201	0.00218	CcSEcCtD
Methyldopa—Mediastinal disorder—Epirubicin—sarcoma	0.002	0.00217	CcSEcCtD
Methyldopa—Mental disorder—Epirubicin—sarcoma	0.00195	0.00211	CcSEcCtD
Methyldopa—Diarrhoea—Etoposide—sarcoma	0.00193	0.00209	CcSEcCtD
Methyldopa—Cardiac disorder—Doxorubicin—sarcoma	0.00191	0.00207	CcSEcCtD
Methyldopa—Flatulence—Epirubicin—sarcoma	0.00191	0.00207	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—sarcoma	0.00187	0.00203	CcSEcCtD
Methyldopa—Dizziness—Etoposide—sarcoma	0.00186	0.00202	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—sarcoma	0.00185	0.00201	CcSEcCtD
Methyldopa—Mental disorder—Doxorubicin—sarcoma	0.0018	0.00196	CcSEcCtD
Methyldopa—Vomiting—Etoposide—sarcoma	0.00179	0.00194	CcSEcCtD
Methyldopa—COMT—lymph node—sarcoma	0.00178	0.0228	CbGeAlD
Methyldopa—Rash—Etoposide—sarcoma	0.00178	0.00193	CcSEcCtD
Methyldopa—Dermatitis—Etoposide—sarcoma	0.00178	0.00193	CcSEcCtD
Methyldopa—Headache—Etoposide—sarcoma	0.00177	0.00192	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—sarcoma	0.00177	0.00192	CcSEcCtD
Methyldopa—ADRA2A—cardiac atrium—sarcoma	0.00173	0.0221	CbGeAlD
Methyldopa—Leukopenia—Epirubicin—sarcoma	0.00173	0.00188	CcSEcCtD
Methyldopa—ADRA2A—uterus—sarcoma	0.00173	0.022	CbGeAlD
Methyldopa—Nausea—Etoposide—sarcoma	0.00167	0.00182	CcSEcCtD
Methyldopa—Myalgia—Epirubicin—sarcoma	0.00165	0.00179	CcSEcCtD
Methyldopa—Arthralgia—Epirubicin—sarcoma	0.00165	0.00179	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00164	0.00178	CcSEcCtD
Methyldopa—Leukopenia—Doxorubicin—sarcoma	0.0016	0.00174	CcSEcCtD
Methyldopa—Oedema—Epirubicin—sarcoma	0.00158	0.00171	CcSEcCtD
Methyldopa—Infection—Epirubicin—sarcoma	0.00157	0.0017	CcSEcCtD
Methyldopa—Nervous system disorder—Epirubicin—sarcoma	0.00155	0.00168	CcSEcCtD
Methyldopa—Thrombocytopenia—Epirubicin—sarcoma	0.00155	0.00168	CcSEcCtD
Methyldopa—Skin disorder—Epirubicin—sarcoma	0.00153	0.00167	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—sarcoma	0.00153	0.00165	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—sarcoma	0.00153	0.00165	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00151	0.00164	CcSEcCtD
Methyldopa—ADRA2A—tendon—sarcoma	0.00151	0.0193	CbGeAlD
Methyldopa—Oedema—Doxorubicin—sarcoma	0.00146	0.00159	CcSEcCtD
Methyldopa—Infection—Doxorubicin—sarcoma	0.00145	0.00158	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00144	0.00156	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—sarcoma	0.00143	0.00156	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—sarcoma	0.00143	0.00155	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—sarcoma	0.00142	0.00154	CcSEcCtD
Methyldopa—Paraesthesia—Epirubicin—sarcoma	0.00142	0.00154	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Epirubicin—sarcoma	0.00136	0.00148	CcSEcCtD
Methyldopa—Constipation—Epirubicin—sarcoma	0.00135	0.00147	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.00133	0.00145	CcSEcCtD
Methyldopa—Paraesthesia—Doxorubicin—sarcoma	0.00131	0.00142	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00126	0.00137	CcSEcCtD
Methyldopa—ADRA2A—testis—sarcoma	0.00125	0.016	CbGeAlD
Methyldopa—Constipation—Doxorubicin—sarcoma	0.00125	0.00136	CcSEcCtD
Methyldopa—Body temperature increased—Epirubicin—sarcoma	0.00125	0.00136	CcSEcCtD
Methyldopa—Hypersensitivity—Epirubicin—sarcoma	0.00116	0.00126	CcSEcCtD
Methyldopa—Body temperature increased—Doxorubicin—sarcoma	0.00116	0.00125	CcSEcCtD
Methyldopa—Asthenia—Epirubicin—sarcoma	0.00113	0.00123	CcSEcCtD
Methyldopa—Diarrhoea—Epirubicin—sarcoma	0.00108	0.00117	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—sarcoma	0.00108	0.00117	CcSEcCtD
Methyldopa—Asthenia—Doxorubicin—sarcoma	0.00105	0.00114	CcSEcCtD
Methyldopa—Dizziness—Epirubicin—sarcoma	0.00104	0.00113	CcSEcCtD
Methyldopa—Vomiting—Epirubicin—sarcoma	0.001	0.00109	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—sarcoma	0.001	0.00109	CcSEcCtD
Methyldopa—Rash—Epirubicin—sarcoma	0.000996	0.00108	CcSEcCtD
Methyldopa—Dermatitis—Epirubicin—sarcoma	0.000995	0.00108	CcSEcCtD
Methyldopa—Headache—Epirubicin—sarcoma	0.00099	0.00107	CcSEcCtD
Methyldopa—Dizziness—Doxorubicin—sarcoma	0.000967	0.00105	CcSEcCtD
Methyldopa—Nausea—Epirubicin—sarcoma	0.000939	0.00102	CcSEcCtD
Methyldopa—Vomiting—Doxorubicin—sarcoma	0.00093	0.00101	CcSEcCtD
Methyldopa—Rash—Doxorubicin—sarcoma	0.000922	0.001	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—sarcoma	0.000921	0.000999	CcSEcCtD
Methyldopa—Headache—Doxorubicin—sarcoma	0.000916	0.000994	CcSEcCtD
Methyldopa—ADRA2A—lymph node—sarcoma	0.000907	0.0116	CbGeAlD
Methyldopa—Nausea—Doxorubicin—sarcoma	0.000868	0.000942	CcSEcCtD
